Thesis Defense: The Impact of Tamoxifen on Cardiac Electrophysiology in the Context of the Tamoxifen-Inducible Cre-Loxp System in Mice
Thesis Defense
The Impact of Tamoxifen on Cardiac Electrophysiology in the Context of the Tamoxifen-Inducible Cre-Loxp System in Mice
Maxwell Albrecht
Graduate Student, Translational Biology, Medicine, and Health
Graduate Research Assistant, Poelzing Lab, Fralin Biomedical Research Institute at VTC
Aug. 4, 2026 at 9 a.m.
Room 3012, 2 Riverside Circle
About this Dissertation
Sudden cardiac death is one of the leading causes of death worldwide, with lethal ventricular arrhythmias being likely responsible for most incidents. The frequency of sudden cardiac death is increasing, presenting the need for more research into the causes and treatments of these deadly arrhythmias. As arrhythmia research increases to meet the need for more effective treatments, there is a distinct need for increased scrutiny into the possible confounding variables present in current models of arrhythmogenic disease. One of the most common and effective models for arrhythmia research is mice, utilizing the tamoxifen-inducible cardiac specific Cre-loxp system. In this system, tamoxifen is used to activate the Cre recombinase protein, made to express only in the heart. This protein targets and removes two inserted artificial loxp sites and the sequence between them, resulting in a gene knockout or other manipulation. This system can be used to target specific proteins known to contribute to arrhythmia formation, while avoiding developmental complications common in constitutive knockouts of cardiac proteins. The cardiac-specific Cre-loxp system is known to have off-target effects, including inflammation, fibrosis, and reduced cardiac performance. Tamoxifen also has effects on cardiac electrophysiology, with the ability to block sodium channels, which can slow conduction and promote arrhythmias. As many studies focus on tamoxifen in the context of its use in human patients, it is unknown whether tamoxifen on its own, as used in the mouse Cre-loxp system, can create an arrhythmogenic phenotype. Albrecht, mentored by Steven Poelzing, conducted studies to determine how tamoxifen impacts cardiac electrophysiology and the expression of key proteins responsible for conduction in an ex vivio mouse model. Albrecht found that tamoxifen could slow conduction, and change action potential duration characteristics, particularly at shorter paced cycle lengths. This indicates that tamoxifen can interfere with cardiac electrophysiology, and that these effects needs to be controlled for in arrhythmia research using models which are exposed to tamoxifen.
More About the Candidate and Project
Education
Virginia Tech, Translational Biology, Medicine, and Health, M.S. Candidate
Virginia Tech, B.S., Systems Biology
Training
Graduate Research Assistant, Poelzing Lab, Fralin Biomedical Research Institute at VTC
Mentors
Steven Poelzing, Ph.D., James and Deborah Petrine Professor, Fralin Biomedical Research Institute at VTC
Committee Members
- James Smyth, Ph.D., Associate Professor, Fralin Biomedical Research Institute at VTC
- Robert Gourdie, Ph.D., Professor and Director, Center for Vascular and Heart Research, Fralin Biomedical Research Institute at VTC
- Scott Johnstone, Ph.D., Assistant Professor, Fralin Biomedical Research Institute at VTC
“Desmoplakin Knockout Attenuates Conduction Velocity Changes in Response to Osmotic Challenge in a Model of Early Stage Arrhythmogenic Cardiomyopathy” Cardiac Arrhythmia Mechanisms, Gordon Research Conference. Barga, Lucca, Italy February 23rd-28th, 2025